patients with migraine attacks accompanied by neurodevelopmental disorders
Conditions
Interventions
Triptan and/or lasmiditan tablets were prescribed for consecutive patients after the diagnosis of migraine attacks and neurodevelopmental disorders. Triptans, eletriptan or zolmitriptan was prescribed
Sponsors
University of Tsukuba, Mito Medical Center, Mito Kyodo General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients were diagnosed with migraine by a certified headache specialist according to the International Classification of Headache 3rd edition. For all patients, brain magnetic resonance imaging was performed, and other organic lesions causing headache were eliminated. Before this study, neurodevelopmental disorders were diagnosed by several specialists.
Exclusion criteria
Exclusion criteria: Patients who could not express their headaches and the effect of the drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-h pain relief and 2-h pain-free rate and adevese events | — |
Countries
Japan
Contacts
Public ContactYasushi Shibata
University of Tsukuba, Mito Medical Center, Mito Kyodo General Hospital Department of Neurosurgery/Headache Clinic
Outcome results
None listed